Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. VeriStrat. Lansdale: HAYES, Inc.. Genetic Testing Publication. 2016 Authors' conclusions Non-small cell lung cancer (NSCLC) encompasses squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. In the United States in 2015, it is estimated that NSCLC was diagnosed in more than 221,000 individuals and resulted in more than 158,000 deaths. More than 80% of lung cancer patients have NSCLC. The VeriStrat test relies on matrix-assisted laser desorption/deionization timeof-flight (MALDI-TOF) mass spectrometry to analyze pretreatment serum from NSCLC patients who are candidates for EGFR TKI therapy. This test has been developed with the goal of identifying patients most likely to benefit from EGFR TKI therapy. The VeriStrat test is considered a proteomic profiling assay, or a test that identifies specific patterns of protein expression in cells, plasma, or tissue. This report focuses on the use of the VeriStrat test as a prognostic tool and to predict response to EGFR TKIs in NSCLC. Indexing Status Subject indexing assigned by CRD MeSH Adenocarcinoma; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32016000953 Date abstract record published 30/08/2016 |